KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Prepaid Assets (2019 - 2025)

Historic Prepaid Assets for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $6.9 million.

  • Royalty Pharma's Prepaid Assets rose 6462.86% to $6.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.9 million, marking a year-over-year increase of 6462.86%. This contributed to the annual value of $6.9 million for FY2025, which is 6462.86% up from last year.
  • Per Royalty Pharma's latest filing, its Prepaid Assets stood at $6.9 million for Q4 2025, which was up 6462.86% from $5.5 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Prepaid Assets registered a high of $90.5 million during Q4 2022, and its lowest value of $2.3 million during Q2 2024.
  • Over the past 5 years, Royalty Pharma's median Prepaid Assets value was $6.6 million (recorded in 2021), while the average stood at $18.2 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first surged by 126510.33% in 2022, then crashed by 9250.51% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Prepaid Assets stood at $6.6 million in 2021, then surged by 1265.1% to $90.5 million in 2022, then tumbled by 80.07% to $18.0 million in 2023, then plummeted by 76.79% to $4.2 million in 2024, then skyrocketed by 64.63% to $6.9 million in 2025.
  • Its Prepaid Assets was $6.9 million in Q4 2025, compared to $5.5 million in Q3 2025 and $4.5 million in Q2 2025.